BioSenic S.A. (BIOS) - Total Assets
Based on the latest financial reports, BioSenic S.A. (BIOS) holds total assets worth €4.50 Million EUR (≈ $5.26 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BioSenic S.A. - Total Assets Trend (2011–2024)
This chart illustrates how BioSenic S.A.'s total assets have evolved over time, based on quarterly financial data. Also see market value of BioSenic S.A. for the company's overall valuation and market capitalisation.
BioSenic S.A. - Asset Composition Analysis
Current Asset Composition (December 2024)
BioSenic S.A.'s total assets of €4.50 Million consist of 34.5% current assets and 65.5% non-current assets. Review total liabilities of BioSenic S.A. to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 8.3% |
| Accounts Receivable | €1.01 Million | 21.3% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €3.00K | 0.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how BioSenic S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See BioSenic S.A. stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioSenic S.A.'s current assets represent 34.5% of total assets in 2024, a decrease from 86.7% in 2011.
- Cash Position: Cash and equivalents constituted 8.3% of total assets in 2024, down from 36.9% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 21.3% of total assets.
BioSenic S.A. Competitors by Total Assets
Key competitors of BioSenic S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
BioSenic S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.53 | 0.40 | 1.00 |
| Quick Ratio | 0.53 | 0.40 | 1.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-3.46 Million | €-3.90 Million | €-52.00K |
BioSenic S.A. - Advanced Valuation Insights
This section examines the relationship between BioSenic S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.53 |
| Latest Market Cap to Assets Ratio | 0.33 |
| Asset Growth Rate (YoY) | -50.4% |
| Total Assets | €4.74 Million |
| Market Capitalization | $1.57 Million USD |
Valuation Analysis
Below Book Valuation: The market values BioSenic S.A.'s assets below their book value (0.33x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: BioSenic S.A.'s assets decreased by 50.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BioSenic S.A. (2011–2024)
The table below shows the annual total assets of BioSenic S.A. from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €4.74 Million ≈ $5.54 Million |
-50.39% |
| 2023-12-31 | €9.56 Million ≈ $11.18 Million |
-67.40% |
| 2022-12-31 | €29.32 Million ≈ $34.28 Million |
+48.31% |
| 2021-12-31 | €19.77 Million ≈ $23.12 Million |
-20.39% |
| 2020-12-31 | €24.84 Million ≈ $29.03 Million |
+10.91% |
| 2019-12-31 | €22.39 Million ≈ $26.18 Million |
-13.05% |
| 2018-12-31 | €25.75 Million ≈ $30.11 Million |
+2.30% |
| 2017-12-31 | €25.17 Million ≈ $29.43 Million |
-34.76% |
| 2016-12-31 | €38.59 Million ≈ $45.11 Million |
-23.42% |
| 2015-12-31 | €50.38 Million ≈ $58.90 Million |
+108.18% |
| 2014-12-31 | €24.20 Million ≈ $28.29 Million |
+88.92% |
| 2013-12-31 | €12.81 Million ≈ $14.98 Million |
-11.15% |
| 2012-12-31 | €14.42 Million ≈ $16.86 Million |
-4.22% |
| 2011-12-31 | €15.05 Million ≈ $17.60 Million |
-- |
About BioSenic S.A.
BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Pha… Read more